Ioannis VOGIATZIS, Evangelos SDOGKOS, Konstantinos KOUTSAMPASOPOULOS, Savas GRIGORIADIS, Sarantis PITTA

Efficacy and Safety of flecainide p.os. in cardioversion ofrecent-onset atrial fibrillation

Aim: The aim of the study was to identify the level of safety and the efficacy of flecainide per o.s. in patients with recent-onset (

PDF

___

1. Miyasaka Y, Barnes M, Gersh B, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25.
2. Alan G, Hylek E, Phillips K, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
3. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18:628-33.
4. Alboni P, Botto GL, Baldi N, Luzi M, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004;351: 2384-91.
5. Mairesse M, Moran P, Gelder I, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 2017;19:1589-623.
6. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998;32:205-10.
7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-68.
8. Andrade JG, Macle L, Nattel S, et al. Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Can J Cardiol 2017;33:965-76.
9. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001;37:542-7.
10. Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide vs sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-4.
11. Lloyd-Jones D, Wang T, Leip E, et al. Lifetime risk for development of atrial fibrillation. The Framingham Heart Study. Circulation 2004;110:1042-6.
12. Hisashi O, Yoshimori A, Syuhei I, et al. Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. Stroke 2018;49:2301-8.
13. Andersen S, Hansen M, Gislason G, et al. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace 2009;11: 886-91.
14. Andrade J, MacGillivray J, Macle L, Yao R, Bennett M, Fordyce C, et al. Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation. Heart Rhythm 2018;15: 9-16.
15. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999;33:966-71.
16. Crijns HJ, van Wijk LM, van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988;9:634-48.
17. Bonora A, Turcato G, Franchi E, et al. Efficacy and safety in pharmacological cardioversion of recentonset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. Intern Emerg Med 2017;12:853-9.
18. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboembolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14.
19. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92.
20. Johnsen SP, Dalby LW, Täckström T, et al. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res 2017;17:714- 22.
21. Dell'Orfano JT, Patel H, Wolbrette DL, et al. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol 1999;83:788-90.
22. Aliot E, Capucci A, Crijns H, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 2011;13:161-73.
23. Boriani G, Biffi M, Capucci A, et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol. 1998;21:2470-4.
24. Ahmadi A, Zolfi-Gol A, Arasteh M. Tachycardia-induced cardiomyopathy. ARYA Atheroscler 2014;10:175-8
25. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121-8
26. Miller M. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm. J Fam Pract 2000;49:1033-46.
27. Crijns H, Weijs B, Fairley A, et al. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol 2014;172:588-94.
28. Boriani G, Diemberger I, Biffi M, et al. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004;64:2741-62.
29. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recentonset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
30. Echt D, Ruskin J. Use of Flecainide for the Treatment of Atrial Fibrillation. Am J Cardiol 2020;125:1123−33.
31. Conde D, Elissamburu P, Lalor N, et al. Conversion of recent-onset atrial fibrillation: Which drug is the best? J Atr Fibrillation 2013;6:910-5.
32. Donovan K, Dobb G, Coombs L, Lee K, Weekes J, Murdock C, et al. Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 1992;70: 50-4.
33. Donovan K, Power B, Hockings B, et al. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995;75:693-7.
34. Alboni P, Botto G, Boriani G, et al. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. Heart 2010;96:546-9.
35. Camm J, Savelieva I. Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self-treat. BMJ 2007;334:637-9.
36. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-7.
37. Deneer VH, Borgh MB, Kingma JH, et al. Oral antiarrhythmic drugs in converting recent-onset atrial fibrillation. Pharm World Sci 2004;26:66-78.